Compare XNET & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XNET | DCTH |
|---|---|---|
| Founded | 2003 | 1988 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 356.5M | 323.1M |
| IPO Year | 2014 | N/A |
| Metric | XNET | DCTH |
|---|---|---|
| Price | $5.66 | $9.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 281.1K | ★ 504.2K |
| Earning Date | 03-12-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8740.73 | N/A |
| EPS | ★ 20.16 | 0.03 |
| Revenue | ★ $401,918,000.00 | $79,603,000.00 |
| Revenue This Year | N/A | $132.21 |
| Revenue Next Year | N/A | $33.88 |
| P/E Ratio | ★ $0.29 | $269.81 |
| Revenue Growth | 27.19 | ★ 251.54 |
| 52 Week Low | $2.64 | $8.12 |
| 52 Week High | $11.03 | $18.23 |
| Indicator | XNET | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 32.72 | 42.60 |
| Support Level | $5.55 | $8.94 |
| Resistance Level | $6.12 | $10.30 |
| Average True Range (ATR) | 0.32 | 0.49 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 22.19 | 30.36 |
Xunlei Ltd is a cloud-based acceleration technology company in China. The company operates a powerful internet platform in China based on cloud computing to provide users with quick and easy access to digital media content through its products and services, Xunlei Accelerator, and cloud acceleration subscription services. It is increasingly extending into mobile devices in part through potentially pre-installed acceleration products in mobile phones Xunlei has developed various value-added services to meet a fuller spectrum of its users' digital media content access and consumption needs.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.